Let's get real... Covid-19 affects way more than t
Post# of 653
(Total Views: 248)
Posted On: 11/06/2020 10:17:16 PM
Let's get real... Covid-19 affects way more than the lungs. There are multiple, safe treatments for thrombisis. Nothing approved for kidney or liver issues (in fact, Remdesivir only makes them worse). Nothing approved for nervous system/brain, pancreas, thyroid, possibly other organ systems. These are all hallmarks of Covid19, but the lungs have a very visible pathology and so get top billing.
So what percentage of severe Covid19 patients present primarily with lung issues? The FDA has indicated it isn't interested in mild/moderate therapies, so at best, we're looking at a subset of the 15% of those considered severe and hospitalized. Let's be generous and say 12%.
Known cases are somewhere in the 10 million area, odds are high that there are at least double and probably more for actual cases in the US... the asymptomatic infected feature heavily, if not visibly with Covid19. Let's ballpark and say 300 million Americans still could be infected, and of those, about 38 million would be candidates for Aviptadil.
Now let's look at the business side of things... Relief has 2,400,000,***000*** shares on the US OTC markets... You read that right, boys and girls, 2.4 Billion with a B shares outstanding, just in the US! Microsoft has 7 Billion shares outstanding, by way of comparison. Google a mere 400 million. (Relief is no Microsoft or Google.) But let's look at the Swiss market... the swiss exchange notes for RLF there are:
Number in issue
2'660'068'581
Quite a few, but what does this mean?
It means that, for the stock to get over $1 and stay there, this company would have to earn ***several hundred million *** in profits.
"Well," you say.. "38 million patients in the US, that's a lot! Surely this stock will be worth $10 soon!"
For this stock to justify a value of $10, relief would probably have to generate revenue of nearly $700 per patient, for EACH and EVERY of the potential 38 million, and that's being generous. A look at reliefs financials is best left for the halloween season...
https://finance.yahoo.com/quote/RLFTF/financials/
Spooky. So it's not the greatest investment (quite a kind assessment), but how about as a treatment for Covid-19 ARDS?
An army of nurses and attendents would be needed to administer.. guess it could be better than nothing. Possibly.
So what percentage of severe Covid19 patients present primarily with lung issues? The FDA has indicated it isn't interested in mild/moderate therapies, so at best, we're looking at a subset of the 15% of those considered severe and hospitalized. Let's be generous and say 12%.
Known cases are somewhere in the 10 million area, odds are high that there are at least double and probably more for actual cases in the US... the asymptomatic infected feature heavily, if not visibly with Covid19. Let's ballpark and say 300 million Americans still could be infected, and of those, about 38 million would be candidates for Aviptadil.
Now let's look at the business side of things... Relief has 2,400,000,***000*** shares on the US OTC markets... You read that right, boys and girls, 2.4 Billion with a B shares outstanding, just in the US! Microsoft has 7 Billion shares outstanding, by way of comparison. Google a mere 400 million. (Relief is no Microsoft or Google.) But let's look at the Swiss market... the swiss exchange notes for RLF there are:
Number in issue
2'660'068'581
Quite a few, but what does this mean?
It means that, for the stock to get over $1 and stay there, this company would have to earn ***several hundred million *** in profits.
"Well," you say.. "38 million patients in the US, that's a lot! Surely this stock will be worth $10 soon!"
For this stock to justify a value of $10, relief would probably have to generate revenue of nearly $700 per patient, for EACH and EVERY of the potential 38 million, and that's being generous. A look at reliefs financials is best left for the halloween season...
https://finance.yahoo.com/quote/RLFTF/financials/
Spooky. So it's not the greatest investment (quite a kind assessment), but how about as a treatment for Covid-19 ARDS?
Quote:
intravenous aviptadil, administered as 3 successive 12 hour infusions of 50/100/150 pmol/kg/hr
An army of nurses and attendents would be needed to administer.. guess it could be better than nothing. Possibly.
(1)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
Scroll down for more posts ▼